July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Pattern Electroretinogram parameters in untreated glaucoma suspects with signs of conversion
Author Affiliations & Notes
  • Andrew Tirsi
    MEETH, New York, New York, United States
  • Benny Wong
    MEETH, New York, New York, United States
  • Peter H Derr
    Diopsys, New Jersey, United States
  • Jaime soria
    CIVE, Ecuador
  • Victoria Rohring
    MEETH, New York, New York, United States
  • Jung Min Lee
    MEETH, New York, New York, United States
  • lukas Schwartz
    MEETH, New York, New York, United States
  • Alberto Gonzalez Garcia
    Diopsys, New Jersey, United States
  • Sung Chul Park
    MEETH, New York, New York, United States
  • Celso Tello
    MEETH, New York, New York, United States
  • Footnotes
    Commercial Relationships   Andrew Tirsi, None; Benny Wong, None; Peter Derr, Diopsys (E); Jaime soria, None; Victoria Rohring, None; Jung Min Lee, None; lukas Schwartz, None; Alberto Gonzalez Garcia, Diopsys (E); Sung Chul Park, None; Celso Tello, Diopsys (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 2446. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Andrew Tirsi, Benny Wong, Peter H Derr, Jaime soria, Victoria Rohring, Jung Min Lee, lukas Schwartz, Alberto Gonzalez Garcia, Sung Chul Park, Celso Tello; Pattern Electroretinogram parameters in untreated glaucoma suspects with signs of conversion. Invest. Ophthalmol. Vis. Sci. 2019;60(9):2446.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : To prospectively monitor progressive changes of retinal ganglion cell (RGC) function in glaucoma suspects (GS) with clinical signs of conversion, contrasted to a group of non-converters, using Pattern Electroretinogram (PERG)

Methods : Sixteen GS subjects (30 untreated eyes) with Humphrey 24-2 visual field test with Glaucoma Hemifield Test “Within Normal Limits”, with MD normal values <-2.00 (dB) and with suspicious optic nerve head were included in the study. Participants were observed over an average of 11.5 ± 3.7 months, during which they were tested with Diopsys NOVA PERG (Diopsys©, Inc. Pine Brook, NJ) and standard automated perimetry two times a year. Based on clinical data, two groups were formed and 9 eyes qualified as clinical converters, while 21 eyes remained as non-converters. Two-way repeated measures ANOVA were conducted as appropriate. This study was IRB approved and informed consent was signed by each subject.

Results : Over the short course of the study, 9 eyes showed signs of conversion according to visual field and Optical coherence tomography definitions. A two-way repeated measures (mixed between-within subjects) ANOVA was used to determine the effect of time (within-subject effects) and group (between subjects effects) over the PERG repeated measures variables (MagD and MagD/mag ratio). Normality of data was assessed by the Shapiro-wilk test and no outliers greater than ± 3 standard deviations were included. There was homogeneity of variance (p> 0.05) and covariances (p>0.05), as assessed by Levene’s test of homogeneity of variance and Box’s M test, respectively. Mauchly’s test of sphericity indicated that the assumption of sphericity was met for the two-way interaction, X2(2) =8.172, p=0.379. There was no statistically significant interaction between Time and PERG parameters, confirming that MagD and MadD/Mag ratio scores did not change significantly over our 3 time points. The main effect of group showed a significant difference in PERG parameters between the converter and non-converter groups F (1,12) = 8.465, p= 0.013, partial Eta2 =0.414 for MagD/Mag Ratio and F (1,12) = 4.853, p= 0.048, partial Eta2 =0.288 for MagD

Conclusions : Slowly converting GS patients over time demonstrate RGC dysfunction associated with increased latency. These findings are clinically significant, especially when deciding when to start treatment

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.